Genentech, Inc. and F. Hoffmann-La Roche AG v.Organon Heist B.V. and N.V. Organon
Brussels (BE) Local Division · UPC-000244
This case concerns review proceedings under R. 197.3 RoP regarding orders to preserve evidence and for inspection issued ex parte in favor of Genentech and Roche concerning European Patent EP 3 401 335 B1, which covers Perjeta® (pertuzumab), a cancer medicine for HER2-positive breast cancer. Organon Heist B.V. and N.V. Organon, who were planning to launch HLX11, a biosimilar of Perjeta® developed with Shanghai Henlius Biotech, sought review of these orders. The Local Division Brussels confirmed the orders, dismissed Organon's requests related to the execution of the orders as inadmissible, and established a schedule for the appointed experts to deliver their report.